Status:
TERMINATED
Variation in Sulphonylurea Response in Type 2 Diabetes
Lead Sponsor:
NHS Tayside
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
35-70 years
Phase:
PHASE4
Brief Summary
The study hypothesis is that people who respond well to sulphonylureas have a different underlying cause for their diabetes than people who respond poorly to this medication. We are using two approach...
Eligibility Criteria
Inclusion
- Type 2 diabetes
- Age \>35 and \< 70
- Age of diabetes diagnosis \>35 and \<70
- White European
- Pre-SU HbA1c \<=10%
- HbA1c (on treatment) \<= 9%
- No myocardial infarction or Acute coronary syndrome in previous year
- No stroke or transient ischaemic attack in previous year
- No or stable (background) retinopathy (no unscheduled laser treatment in the last 6 months)
- eGFR \> 60mls/min
- No Proteinuria \>30mg/dl on multistix 10SG
- No active foot ulceration or infection
- Liver ALT ≤ twice the upper limit of the reference range
- Contactable by telephone
Exclusion
- Type 1 diabetes
- HbA1c \>10% prior to commencing SU
- HbA1c\>9% on SU treatment
- Recent MI or Stroke within last 12 months
- Pre-proliferative or proliferative retinopathy
- eGFR\<60 ml/min
- Proteinuria \>30mg/dl on multistix 10SG
- Active foot ulceration or infection
- Liver ALT \> twice the upper limit of the reference range
- Female planning to conceive within the study period
- Any other significant medical reason for exclusion as determined by the investigator
Key Trial Info
Start Date :
June 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 3 2011
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT00738088
Start Date
June 1 2007
End Date
March 3 2011
Last Update
May 3 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
NHS Tayside
Dundee, United Kingdom, DD1 9SY